

Supplemental Approvals

Generic Name (Trade Name—Company)

April 4, 2018

Exenatide extended-release

(Bydureon—AstraZeneca)

Approval of exenatide ER expanded for use with basal insulin to treat uncontrolled T2D

Uses/Notes

FDA has approved exenatide extended-release (ER) for injectable suspension as add-on therapy to basal insulin in adults with type 2 diabetes (T2D) with inadequate glycemic control despite taking one or more antidiabetic medications and making diet and exercise changes.

The expanded use is based on results from the 28-week DURATION-7 study, which examined the effect of exenatide ER or placebo as add-on therapy to insulin glargine, with or without metformin, in adults with T2D. Mean A1C was reduced by 0.9% in the exenatide extended-release group compared to 0.2% in the placebo group in patients with a mean baseline A1C of 8.5%.

Furthermore, 32.5% of patients in the exenatide extended-release group reached an A1C of less than 7.0% compared to 7.0% of patients in the placebo group.

No new safety data were found in the DURATION-7 study. Overall hypoglycemia was similar between the groups, with no reported major hypoglycemia. In both arms, the same percentage of patients reported minor hypoglycemia.

Like other GLP-1 receptor agonists, the risk of hypoglycemia is increased when exenatide extended-release is coadministered with insulin. Prescribers should consider lowering the dose of insulin when coadministering exenatide extended-release.

The most common adverse events are nausea, diarrhea, headache, vomiting, constipation, injection-site pruritus, injection-site nodule, and dyspepsia.

Source URL:

<http://aphanet.org/supplemental-approvals/approval-exenatide-er-expanded-use-basal-insulin-treat-uncontrolled-t2d>

APhA DrugInfoLine is an official publication of, and is owned and copyrighted by the American Pharmacists Association, the national professional society of pharmacists. Materials in APhA DrugInfoLine do not necessarily represent the policy, recommendations, or endorsement of APhA. The publisher, authors, editors, reviewers, and contributors have taken care to ensure that information contained in APhA DrugInfoLine is accurate and current; however, they shall have no liability to any person or entity with regard to claims, losses, or damages caused or alleged to be caused, directly or indirectly, by use of any information contained in the publication. All decisions about drug therapy must be based on the independent judgment of the clinician. Copyright © 2000–2011, American Pharmacists Association. All rights reserved.